Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Discontinuation of TyrosIne Kinase Inhibitors (ITK) in Chronic Myeloid Leukemia (LMC) and Impact on the Immune System: a Randomized Comparative Study of Two Therapeutic Strategies

NCT05753384 is registered in ClinicalTrials.gov with Poitiers University Hospital as lead sponsor.

NCT NCT05753384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05753384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Discontinuation of TyrosIne Kinase Inhibitors (ITK) in Chronic Myeloid Leukemia (LMC) and Impact on the Immune System: a Randomized Comparative Study of Two Therapeutic Strategies
Lead sponsor
Poitiers University Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 1, 2023
Completion date
December 1, 2029
Enrollment
170 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, tyrosine kinase inhibitors